|Videos|November 15, 2021
Dr Derek Chew on the VICTORIA Trial and the Cost-effectiveness of Vericiguat
Author(s)Mary Caffrey
The VICTORIA study found vericiguat to be more cost-effective than placebo when using current societal benchmarks for health care value in the United States. Derek Chew, MD, now an assistant professor at the University of Calgary, conducted economic evaluations for the VICTORIA trial while with the Duke Clinical Research Institute. Results were presented at the 2021 AHA Scientific Sessions. Here, he explains why vericiguat is more cost-effective for patients with heart failure with reduced ejection fraction.
Advertisement
Internal server error